Germline


Journal

Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017

Informations de publication

Date de publication:
10 2019
Historique:
received: 14 06 2019
accepted: 15 08 2019
pubmed: 19 10 2019
medline: 21 7 2020
entrez: 19 10 2019
Statut: epublish

Résumé

Ultra-hypermutation (>100 mutations/Mb) is rare in childhood cancer genomes and has been primarily reported in patients with constitutional mismatch repair deficiency (CMMRD) caused by biallelic germline mismatch repair (MMR) gene mutations. We report a 5-yr-old child with classic clinical features of CMMRD and an ultra-hypermutated medulloblastoma with retained MMR protein expression and absence of germline MMR mutations. Mutational signature analysis of tumor panel sequencing data revealed a canonical DNA polymerase-deficiency-associated signature, prompting further genetic testing that uncovered a germline

Identifiants

pubmed: 31624068
pii: mcs.a004499
doi: 10.1101/mcs.a004499
pmc: PMC6824253
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
Poly-ADP-Ribose Binding Proteins 0
DNA Polymerase II EC 2.7.7.7
POLE protein, human EC 2.7.7.7

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019 Lindsay et al.; Published by Cold Spring Harbor Laboratory Press.

Références

J Med Genet. 2014 Jun;51(6):355-65
pubmed: 24737826
Oncotarget. 2018 Oct 23;9(83):35458-35469
pubmed: 30459937
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Gynecol Oncol. 2017 Jan;144(1):146-152
pubmed: 27894751
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Int J Oncol. 2014 Jul;45(1):77-81
pubmed: 24788313
Nat Genet. 2015 Mar;47(3):257-62
pubmed: 25642631
Fam Cancer. 2015 Sep;14(3):437-48
pubmed: 25860647
J Clin Oncol. 2016 Jul 1;34(19):2206-11
pubmed: 27001570
Eur J Cancer. 2017 Oct;84:290-303
pubmed: 28846956
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Crit Rev Oncol Hematol. 2017 May;113:242-248
pubmed: 28427513
J Pathol. 2013 Jun;230(2):148-53
pubmed: 23447401
Nat Rev Cancer. 2015 Mar;15(3):181-94
pubmed: 25673086
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Eur J Hum Genet. 2016 Jul;24(7):1089-92
pubmed: 26648449
Nat Genet. 2014 Aug;46(8):912-918
pubmed: 25017105
Genome Res. 2014 Nov;24(11):1740-50
pubmed: 25228659
Hum Mutat. 2011 Aug;32(8):894-9
pubmed: 21520341
Eur J Cancer. 2014 Mar;50(5):987-96
pubmed: 24440087
Hum Mol Genet. 2013 Jul 15;22(14):2820-8
pubmed: 23528559
Int J Cancer. 2015 Jul 15;137(2):320-31
pubmed: 25529843
Genet Med. 2016 Apr;18(4):325-32
pubmed: 26133394
J Pathol. 2013 Jan;229(1):99-110
pubmed: 22899370
Genome Med. 2015 Mar 28;7(1):31
pubmed: 25821521
Cancer Discov. 2018 Dec;8(12):1518-1528
pubmed: 30442708
Histopathology. 2018 Jan;72(2):248-258
pubmed: 28795426
Neuro Oncol. 2015 Oct;17(10):1356-64
pubmed: 25740784
Mod Pathol. 2017 Dec;30(12):1748-1759
pubmed: 28776572
Clin Cancer Res. 2017 Jun 1;23(11):e32-e37
pubmed: 28572265
Cancer Discov. 2016 Nov;6(11):1230-1236
pubmed: 27683556
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Am J Surg Pathol. 2016 Jul;40(7):972-81
pubmed: 26975040
Fam Cancer. 2017 Jan;16(1):67-71
pubmed: 27573199
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Clin Cancer Res. 2016 Jun 15;22(12):2865-73
pubmed: 26763250
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cancer. 2015 Feb 1;121(3):386-94
pubmed: 25224212
Genet Med. 2018 Aug;20(8):890-895
pubmed: 29120461
Cancer Res. 2016 Apr 15;76(8):2057-9
pubmed: 27197248
Cancer Med. 2014 Dec;3(6):1527-38
pubmed: 25124163
Am J Surg Pathol. 2017 Aug;41(8):1121-1128
pubmed: 28498284
Mol Cell. 2016 Jun 2;62(5):745-55
pubmed: 27259205
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
Oncotarget. 2017 Apr 18;8(16):26732-26743
pubmed: 28423643
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027

Auteurs

Holly Lindsay (H)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.

Sarah Scollon (S)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.

Jacquelyn Reuther (J)

Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Horatiu Voicu (H)

Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Surya P Rednam (SP)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.

Frank Y Lin (FY)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.

Kevin E Fisher (KE)

Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Murali Chintagumpala (M)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.

Adekunle M Adesina (AM)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

D Will Parsons (DW)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.
Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.
Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Sharon E Plon (SE)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas 77030, USA.
Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.
Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Angshumoy Roy (A)

Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA.
Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas 77030, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH